W.L. Gore & Associates

Mitico is a company specializing in advanced carbon capture technology aimed at significantly reducing carbon dioxide emissions from various industrial sources. Utilizing its innovative patent-pending granulated metal carbonate sorption technology developed at Caltech, Mitico effectively captures over 95% of CO2 emitted from post-combustion point sources, such as gas-fired power plants and waste-to-energy facilities. By providing carbon capture, utilization, and storage (CCUS) as a service, Mitico enables clients to mitigate their carbon footprints at a competitive cost compared to conventional methods. The company's focus is on helping point source emitters implement effective solutions for mass reduction of carbon emissions.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

InnAVasc Medical, Inc., established in 2013 and headquartered in Durham, North Carolina, specializes in the design and development of medical devices for vascular access in hemodialysis. The company's primary product, the Bullet Proof Vascular Access Graft, is an arteriovenous graft featuring two multilayer cannulation chambers, engineered to resist posterior and sidewall needle penetration and injury, thereby enhancing the safety and longevity of vascular access for hemodialysis patients.

PhysioLogic Devices, Inc. is a California-based company established in 2013 that specializes in the development of advanced implantable products aimed at transforming the treatment of insulin-requiring diabetes. The company focuses on creating innovative technologies, including an implantable insulin pump that works in conjunction with a glucose sensor. This system automates glucose control by delivering insulin directly to the intraperitoneal space for uptake by the liver, effectively normalizing glucose physiology. By providing a solution that enables patients with Type 1 diabetes to manage their condition more effectively, PhysioLogic Devices seeks to alleviate the burdens associated with traditional insulin therapy.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Quellan, Inc. is a designer and developer of analog signal processing and radio frequency noise cancellation integrated circuits (IC) based in Santa Clara, California. Founded in 2001, the company specializes in creating innovative solutions for various markets, including automotive, computing, data centers, storage, consumer electronics, and wireless applications. Quellan's product offerings include noise cancellers that detect and counteract unwanted noise in signal paths, system developer kits for mobile television and GPS, quad and single lane extenders for maintaining analog signal integrity in data center equipment, as well as evaluation boards, cable modules, and active cables. These products are utilized in a range of applications, such as active cables, linecards, backplanes, and mobile television systems. As of 2009, Quellan operates as a subsidiary of Intersil Corp.